In the Swedish Cancer Society’s latest call, researchers at the Department of Medicine, Huddinge (MedH) have been awarded a total of SEK 65 650 000 for the years 2027-2029. The funding covers 20 research projects and one planning group.
A total of SEK 65 200 000 has been awarded in project grants and SEK 450 000 to the planning group Swedish Lymphoma Group (SLG). The recipients, projects and grant amounts are presented below.
Evren Alici , HERM
Granted: SEK 1 600 000 for 2027-2028.
Project title: Reprogramming the immune synapse to enable persistent universal NK cell therapies
Ann-Sofie Backman , GUT
Granted: SEK 800 000 for 2027.
Project title: Mesalamine for colorectal cancer prevention program in Lynch syndrome-a multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with Mesalamine(5-ASA) or placebo in LS carriers
Annika Bergquist , GUT
Granted: SEK 4 500 000 for 2027-2029.
Project title: Primary Sclerosing Cholangitis – A Premalignant Disease
Martin Bergö , ICCA
Granted: SEK 6 000 000 for 2027-2029.
Project title: Defining how nuclear CCL28, metastasis-promoting immune cells, and BACH1 drive tumor progression and metastasis
Niklas Björkström , CIM
Granted: SEK 3 000 000 for 2027-2028.
Project title: Decoding human determinants of tumor immune exclusion using monozygotic twins
Yenan Bryceson , HERM
Granted: SEK 3 500 000 for 2027-2028.
Project title: Understanding and harnessing lymphocyte cytotoxicity against solid tumors
Antonino Cassotta , HERM
Granted: SEK 3 000 000 for 2027-2029.
Project title: Dissecting the myeloma-reactive TCR repertoire to develop predictive models of clinical response to T cell engager therapy
Benedict Chambers , CIM
Granted: SEK 1 600 000 for 2027-2028.
Project title: Continued studies into the adhesion molecule JAML in anti-tumor immune responses
Rongrong Fan , GUT
Granted: SEK 1 000 000 for 2027.
Project title: X-linked epigenetic enzyme as a sex-specific regulator of tumor immunity in liver cancer
Sten Eirik Jacobsen , HERM
Granted: SEK 4 500 000 for 2027-2029.
Project title: Identification, characterization and therapeutic targeting of the stem cells of myeloid malignancies
Sören Lehmann , HERM
Granted: SEK 7 500 000 for 2027-2029.
Project title: Harnessing the epigenome and immune system to improve treatment of acute myeloid leukemia (AML) with focus on bcl-2 inhibition and TP53-mutated patients
Andreas Lennartsson , HERM
Granted: SEK 4 500 000 for 2027-2029.
Project title: Targeting epigenetic plasticity in pediatric acute leukemia
Vanessa Lundin , HERM
Granted: SEK 2 400 000 for 2027-2029.
Project title: Developmental Stem Cell Heterogeneity as a Determinant of Blood Cancer Risk
Jakob Michaëlsson , CIM
Granted: SEK 3 000 000 for 2027-2029.
Project title: Dissecting the functional regulation of lung tumor-infiltrating human NK Cells
Hong Qian , HERM
Granted: SEK 2 500 000 for 2027-2028.
Project title: Targeting leukemia niche to identify new therapeutic option
Stefano Romeo , CeRM
Granted: SEK 800 000 for 2027.
Project title: ELUCIDATING THE GENETIC ARCHITECTURE OF HEPATOCELLULAR CARCINOMA
Johan Sandberg , CIM
Granted: SEK 3 000 000 for 2027-2029.
Project title: The potential of innate-like MAIT cells in cancer: Immunobiology, tissue-specific specialization and immunotherapy
Staffan Strömblad , ICCA
Granted: SEK 6 000 000 for 2027-2029.
Project title: Cell-matrix interactions in cancer
Björn Wahlin , HERM
Granted: SEK 3 000 000 for 2027-2029.
Project title: Improved therapy and precision medicine for lymphoma
Martin Wohlwend , ICCA
Granted: SEK 3 000 000 for 2027-2029.
Project title: Identification and targeting of oncogenic RNA domains
Kristina Sonnevi , HERM – planning group
Granted: SEK 450 000 for 2027-2029.
Planning group: Swedish Lymphoma Group (SLG)